Skip to main content
SpringerLink
Log in

Relationship of adipokines and non-esterified fatty acid to the insulin resistance in non-diabetic individuals

  • Original Articles
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background: Altered secretion of adipokines and non-esterified fatty acid (NEFA) seems to play a pivotal role in the abdominal obesity-related insulin resistance (IR). Aim: To determine semi-quantitatively the impact of serum NEFA, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), leptin, adiponectin, and resistin levels on IR measured by homeostasis model assessment (HOMA-IR). Material/subjects: Seventy-four Caucasian subjects forming 3 age-, and sex-matched groups were included into the study [Group 1 and 2: non-diabetic obese patients, no.= 25, body mass index (BMI): 28–39.9 kg/m2, no.=25, BMI≥40 kg/m2, respectively, and Group 3: 24 healthy, normal weight control subjects]. Methods: Serum levels of NEFA and adipokines as well as other metabolic variables including HOMA-IR were measured. Results: HOMA-IR was associated positively with BMI, waist circumference, serum NEFA, leptin, IL-6, and TNF-α levels, negatively with adiponectin, with no significant relation to resistin. In multiple regression analyses, of these factors leptin was a strong, IL-6 and adiponectin were weak independent predictors of HOMA-IR, while the others were not significant determinants of HOMA-IR. However, even together, they explained only 35–36% of variance of HOMA-IR. Conclusions: Although IR has associations with many of the investigated parameters, of these, only serum level of leptin, and in lesser degree IL-6 and adiponectin are independent determinants of the severity of IR. Moreover, even together they explain only a minority of variance IR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Staiger H, Häring HU. Adipocytokines: fat-derived humoral mediators of metabolic homeostasis. Exp Clin Endocrinol Diabetes 2005, 113: 67–79.

    Article  PubMed  CAS  Google Scholar 

  2. Yudkin JS. Inflammation, obesity, and the metabolic syndrome. Horm Metab Res 2007, 39: 707–9.

    Article  PubMed  CAS  Google Scholar 

  3. Marette A. Mediators of cytokine-induced insulin resistance in obesity and other inflammatory settings. Curr Opin Clin Nutr Metab Care 2002, 5: 377–83.

    Article  PubMed  CAS  Google Scholar 

  4. Koutsari C, Jensen MD. Thematic review series: patient-oriented research. Free fatty acid metabolism in human obesity. J Lipid Res 2006, 47: 1643–50.

    Article  PubMed  CAS  Google Scholar 

  5. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86: 1930–5.

    Article  PubMed  CAS  Google Scholar 

  6. Yamamoto Y, Hirose H, Saito I, et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond) 2002, 103: 137–42.

    Article  CAS  Google Scholar 

  7. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257: 79–83.

    Article  PubMed  CAS  Google Scholar 

  8. Matsubara M, Maruoka S, Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 2002, 147: 173–80.

    Article  PubMed  CAS  Google Scholar 

  9. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000, 20: 1595–9.

    Article  PubMed  CAS  Google Scholar 

  10. Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med 1999, 130: 671–80.

    Article  PubMed  CAS  Google Scholar 

  11. Matsubara M, Katayose S, Maruoka S. Decreased plasma adiponectin concentrations in nondiabetic women with elevated homeostasis model assessment ratios. Eur J Endocrinol 2003, 148: 343–50.

    Article  PubMed  CAS  Google Scholar 

  12. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7: 941–6.

    Article  PubMed  CAS  Google Scholar 

  13. Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002, 109: 1345–50.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  14. Kougias P, Chai H, Lin PH, Yao Q, Lumsden AB, Chen C. Effects of adipocyte-derived cytokines on endothelial functions: implication of vascular disease. J Surg Res 2005, 126: 121–9.

    Article  PubMed  CAS  Google Scholar 

  15. Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 2003, 111: 225–30.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  16. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005, 111: 932–9.

    Article  PubMed  CAS  Google Scholar 

  17. Azuma K, Katsukawa F, Oguchi S, et al. Correlation between serum resistin level and adiposity in obese individuals. Obes Res 2003, 11: 997–1001.

    Article  PubMed  CAS  Google Scholar 

  18. Lee JH, Chan JL, Yiannakouris N, et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003, 88: 4848–56.

    Article  PubMed  CAS  Google Scholar 

  19. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, et al. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003, 88: 5452–5.

    Article  PubMed  CAS  Google Scholar 

  20. Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 2003, 149: 331–5.

    Article  PubMed  CAS  Google Scholar 

  21. Chen CC, Li TC, Li CI, Liu CS, Wang HJ, Lin CC. Serum resistin level among healthy subjects: relationship to anthropometric and metabolic parameters. Metabolism 2005, 54: 471–5.

    Article  PubMed  CAS  Google Scholar 

  22. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 2005, 366: 1059–62.

    Article  PubMed  Google Scholar 

  23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412–9.

    Article  PubMed  CAS  Google Scholar 

  24. Glund S, Krook A. Role of interleukin-6 signaling in glucose and lipid metabolism. Acta Physiol (Oxf) 2008, 192: 37–48.

    Article  CAS  Google Scholar 

  25. Hoene M, Weigert C. The role of interleukin-6 in insulin resistance, body fat distribution and energy balance. Obes Rev 2008, 9: 20–9.

    PubMed  CAS  Google Scholar 

  26. Spangenburg EE. Point, counterpoint: Interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol 2007, 102: 820.

    Article  PubMed  Google Scholar 

  27. Yusuf S, Hawken S, Ounpuu S, et al. INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005, 366: 1640–9.

    Article  PubMed  Google Scholar 

  28. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000, 23: 57–63.

    Article  PubMed  CAS  Google Scholar 

  29. Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003, 46: 459–69.

    PubMed  CAS  Google Scholar 

  30. Filippatos TD, Derdemezis CS, Gazi IF, et al. Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest 2008, 38: 71–2.

    Article  PubMed  CAS  Google Scholar 

  31. Oki K, Yamane K, Kamei N, Nojima H, Kohno N. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol (Oxf) 2007, 67: 796–800.

    Article  CAS  Google Scholar 

  32. Pfützner A, Hanefeld M, Lübben G, et al. Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk — results from the PIOSTAT study. Horm Metab Res 2007, 39: 764–8.

    Article  PubMed  CAS  Google Scholar 

  33. Chen CC, Li TC, Li CI, et al. The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women. Metabolism 2007, 56: 1216–20.

    Article  PubMed  CAS  Google Scholar 

  34. Kowalska I, Straczkowski M, Adamska A, et al. Serum retinol binding protein 4 is related to insulin resistance and non-oxidative glucose metabolism in lean and obese women with normal glucose tolerance. J Clin Endocrinol Metab 2008, 93: 2786–9.

    Article  PubMed  CAS  Google Scholar 

  35. Promintzer M, Krebs M, Todoric J, et al. Insulin resistance is unrelated to circulating retinol binding protein and protein C inhibitor. J Clin Endocrinol Metab 2007, 92: 4306–12.

    Article  PubMed  CAS  Google Scholar 

  36. Silha JV, Nyomba BL, Leslie WD, Murphy LJ. Ethnicity, insulin resistance, and inflammatory adipokines in women at high and low risk for vascular disease. Diabetes Care 2007, 30: 286–91.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Laboratory Medicine, School of Medicine, University of Pécs, Pécs, Hungary

    A. Peti & G. L. Kovacs

  2. 1st Department of Medicine, University of Debrecen, Medical and Health Science Center, Debrecen, Hungary

    A. Juhasz, Z. Varga, I. Seres & G. Paragh

  3. 1st Department of Medicine, School of Medicine, University of Pécs, Pécs, Hungary

    P. Kenyeres & L. Bajnok MD, PhD

  4. Medipolis Knowledge Center, Pécs, Hungary

    G. L. Kovacs

Authors
  1. A. Peti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Juhasz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Kenyeres
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Z. Varga
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. Seres
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. L. Kovacs
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Paragh
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L. Bajnok MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Bajnok MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peti, A., Juhasz, A., Kenyeres, P. et al. Relationship of adipokines and non-esterified fatty acid to the insulin resistance in non-diabetic individuals. J Endocrinol Invest 34, 21–25 (2011). https://doi.org/10.1007/BF03346690

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03346690

Keywords

Search

Navigation